Effective prevention of atherosclerosis by non-viral delivery of CRISPR/Cas9
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: CRISPR and Genetic Engineering · Viral Infections and Immunology Research · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort10.1016/S0140-6736(20)32233-9 ↗
2. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 201310.1016/S0140-6736(15)00551-6 ↗
3. China cardiovascular diseases report 2015: a summary
4. Assessment of low-gradient aortic stenosis with dobutamine10.1161/CIRCULATIONAHA.105.600684 ↗
5. Lipoproteins and cardiovascular risk-from genetics to CHD prevention
6. Lipid parameters for measuring risk of cardiovascular disease10.1038/nrcardio.2010.223 ↗
7. Blood pressure, LDL cholesterol, and intima-media thickness: A test of the “response to injury” hypothesis of atherosclerosis
8. Lipid lowering with PCSK9 inhibitors10.1038/nrcardio.2014.84 ↗
9. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis10.1038/ncomms13457 ↗
10. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel10.1093/eurheartj/ehx144 ↗
11. Drug-induced aches and pains10.1126/scitranslmed.3007631 ↗
12. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia10.1038/ng1161 ↗
13. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis10.1016/j.jacc.2005.01.051 ↗
14. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease10.1056/NEJMoa054013 ↗
15. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia10.1038/nsmb1235 ↗
16. Molecular biology of PCSK9: its role in LDL metabolism10.1016/j.tibs.2006.12.008 ↗
17. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial10.1016/S0140-6736(17)32290-0 ↗
18. Lloyd-Jones · J. Am. Coll. Cardiol. · 2017 · 70 · 178510.1016/j.jacc.2017.07.745 ↗
19. Cognition after lowering LDL-Cholesterol with evolocumab10.1016/j.jacc.2020.03.039 ↗
20. PCSK9-gene-silencing, cholesterol-lowering drug impresses10.1038/s41587-019-0351-4 ↗
21. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events10.1056/NEJMoa1501031 ↗
22. Advances in lipid-lowering therapy through gene-silencing technologies10.1038/nrcardio.2018.3 ↗
23. PCSK9: a key modulator of cardiovascular health10.1161/CIRCRESAHA.114.301621 ↗
24. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins10.1161/CIRCULATIONAHA.118.034710 ↗
25. Genome engineering using the CRISPR-Cas9 system
26. CRISPR/Cas9-based engineering of the epigenome10.1016/j.stem.2017.09.006 ↗
27. In dogs, CRISPR fixes a muscular dystrophy10.1126/science.361.6405.835 ↗
28. Development of a CRISPR/Cas9-based therapy for hutchinson-gilford progeria syndrome10.1038/s41591-018-0338-6 ↗
29. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing10.1161/CIRCRESAHA.115.304351 ↗
30. CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo-brief report10.1161/ATVBAHA.116.307227 ↗
31. Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol10.1038/nbt.4182 ↗
32. Triple targeting delivery of CRISRP/Cas9 to reduce the risk of cardiovascular diseases10.1002/ange.201903618 ↗
33. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles10.1002/adma.201902575 ↗
34. CRISPR/Cas9 delivery mediated with hydroxyl-rich nanosystems for gene editing in aorta10.1002/advs.201900386 ↗
35. A lactose-derived CRISPR/Cas9 delivery system for efficient genome editing in vivo to treat orthotopic hepatocellular carcinoma10.1002/advs.202001424 ↗
36. Effective codelivery of lncRNA and pDNA by pullulan-based nanovectors for promising therapy of hepatocellular carcinoma10.1002/adfm.201603041 ↗
37. Versatile types of MRI-visible cationic nanoparticles involving pullulan polysaccharides for multifunctional gene carriers10.1021/acsami.5b11016 ↗
38. Multifunctional cationic nanosystems for nucleic acid therapy of thoracic aortic dissection10.1038/s41467-019-11068-1 ↗
39. Effective delivery of hypertrophic miRNA inhibitor by cholesterol-containing nanocarriers for preventing pressure overload induced cardiac hypertrophy10.1002/advs.201900023 ↗
40. The asialoglycoprotein receptor: relationships between structure, function, and expression10.1152/physrev.1995.75.3.591 ↗
41. Efficient liver targeting by polyvalent display of a compact ligand for the asialoglycoprotein receptor10.1021/jacs.6b12964 ↗
42. Targeted gene delivery into HepG2 cells using complexes containing DNA, cationized asialoorosomucoid and activated cationic liposomes10.1016/S0168-3659(03)00360-2 ↗